While tumor necrosis factor (TNF) deficiency is associated with a higher incidence of tuberculosis, excessive production of TNF is associated with an exaggerated inflammatory response that can result in mycobacterial immune reconstitution inflammatory syndrome (IRIS).
Immune reconstitution inflammatory syndrome (IRIS) is a paradoxical clinical worsening of a known condition—or the appearance of a new condition—after a patient with HIV initiates antiretroviral therapy (ART). Frequently associated with mycobacteria, which can cause tuberculosis (TB), among other diseases, IRIS typically requires treatment with corticosteroids. However, patients’ clinical response to corticosteroid treatment is not always adequate, and that challenge has clinicians looking to anti—tumor necrosis factor (TNF) therapies for alternatives.
While TNF deficiency is associated with a higher incidence of TB, excessive production of TNF is associated with an exaggerated inflammatory response that can result in mycobacterial IRIS. A new case report published in Open Forum Infectious Diseases suggests that biosimilar infliximab, an anti-TNF, could provide a therapeutic option for patients whose IRIS is refractory to corticosteroids.
The case report first discusses Patient 1, a 33-year-old African American man who was diagnosed with HIV 3 months prior to being admitted to the hospital with a high fever, where a culture confirmed the presence of drug-sensitive Mycobacterium tuberculosis. After 3 weeks of anti-TB therapy, the patient initiated anti-HIV treatment with raltegravir, emtricitabine, and tenofovir. After 4 weeks, the patient developed a fever and enlarged lymph nodes. When Patient 1 did not show clinical improvement after treatment with naproxen and methylprednisolone, and other possible pathogens had been ruled out, the clinicians initiated treatment with biosimilar infliximab, CT-P13 at a dose of 5 mg/kg every 2 weeks for a total of 3 infusions.
During the third infusion, Patient 1 experienced an anaphylactic reaction despite premedication with hydrocortisone and paracetamol (the reaction was resolved with adrenaline, hydrocortisone, and infused saline solution). In the weeks following his treatment with biosimilar infliximab, Patient 1’s fever resolved and his lymph nodes were no longer palpable.
The authors also report on Patient 2, a 44-year-old white woman diagnosed with HIV in 2003 who had not taken ART in the 2 years prior to her 2015 admission to the hospital with fever and diarrhea—the fever resolved after anti-TB therapy. Several weeks later, a biopsy of her colon yielded Mycobacterium bovis. After 5 weeks of antimycobaterial therapy, Patient 2 initiated anti-HIV therapy, but developed abdominal pain and symptoms indicating partial obstruction of the intestine that required hospitalization. Patient 2’s symptoms resolved with methylprednisolone, but after tapering the corticosteroid, she required several subsequent hospitalizations for a return of the partial obstruction of the intestine.
Because the corticosteroid could not be withdrawn without worsening Patient 2’s condition, the clinicians initiated treatment with biosimilar infliximab (CT-P13, as with Patient 1) at 5 mg/kg every 2 weeks for a total of 3 infusions. Patient 2’s clinical condition improved, and laboratory values returned to normal with no indications of a relapse of mycobacterial disease. Methylprednisolone was tapered and eventually withdrawn 6 weeks after the first infliximab dose with no difficulty. No adverse events related to treatment with infliximab were recorded for Patient 2.
A meta-analysis of 40 studies and 1048 cases showed that tuberculosis-associated IRIS was reported in 18% of patients with HIV who were initiating ART, and that a 2% mortality rate and a 25% morbidity rate were directly attributable to TB-associated IRIS. “Treatment for the more severe and life-threatening clinical forms of IRIS has not undergone any innovative changes in recent decades beyond the use of corticosteroids,” the authors note. While their experience in using biosimilar infliximab with patients who have HIV is limited, and while Patient 1’s anaphylactic reaction to treatment is noteworthy, they believe that biosimilar infliximab could be a promising alternative for patients who have severe, corticosteroid-refractory mycobacterial IRIS.
Sandoz Report: A Unified Approach to Overcoming Drug Shortages
October 10th 2024A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% of hospital systems in the US, recommending policy changes and actions to address the ongoing issue, which has caused treatment delays and increased costs.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
AAM Report: Despite Massive Savings, Patient OOP Costs on Biosimilars, Generics Remain High, Part 2
September 24th 2024Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics and biosimilars saved $445 billion in 2023, their potential is hindered by high patient costs, drug shortages, and ineffective policies, underscoring the need for reforms to fully realize their benefits.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Expanding Biosimilar Adoption: Insights and Strategies With Dr Sophia Humphreys
September 16th 2024Sophia Humphreys, PharmD, MHA, BCBBS, director of system formulary management at Sutter Health, discusses the challenges of expanding biosimilars into new therapeutic areas and highlights the role of education, competitive pricing, and integrated delivery networks in improving adoption and market growth.
Real-World Study Shows Comparable Outcomes Between CT-P13, Remicade in RA
September 14th 2024A real-world study of the biosimilar infliximab-dyyb (CT-P13; Inflectra) in rheumatoid arthritis (RA) reported the majority of patients who initiated CT-P13 switched from the reference product (Remicade) or another biologic or targeted synthetic disease-modifying antirheumatic drug.